In one study, carried out by Akuta et al., canagliflozin, an SGLT-2 inhibitor was used for a long term to treat seven patients diagnosed with NAFLD and T2DM. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.